Related Experiment Video

Updated: Nov 2, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.3K

Progress in the therapeutic inhibition of Cdc42 signalling

Natasha P Murphy1, Helen R Mott1, Darerca Owen1

  • 1Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, U.K.

Biochemical Society Transactions
|June 8, 2021
PubMed

Insights

Cdc42, a key regulator of cell functions, is overexpressed in cancers, driving tumor growth and metastasis. Targeting Cdc42 and its pathways offers promising new cancer therapeutic strategies.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Cdc42, a Rho GTPase, regulates actin cytoskeleton, cell motility, polarity, and cell cycle.
  • It is essential for Ras-driven cell transformation and is overexpressed in various cancers, correlating with poor prognosis.
  • Deregulation of Cdc42 contributes to tumor metastasis.

Purpose of the Study:

  • To review progress in targeting Cdc42 and its associated signaling pathways for cancer therapy.
  • To explore novel therapeutic modalities and strategies for Cdc42 inhibition.

Main Methods:

  • Literature review of research on Cdc42 signaling pathways and therapeutic targeting.
  • Analysis of various inhibition strategies, including targeting lipid modification, protein interactions, and downstream effectors.

Main Results:

  • Cdc42 and its pathway components are crucial targets for cancer therapeutics.
  • Several strategies are under consideration for inhibiting Cdc42 activity and signaling.

Conclusions:

  • Targeting Cdc42, its regulators (GEFs, GDIs), and effectors presents a viable therapeutic avenue for cancer treatment.
  • New approaches and modalities are being developed to inhibit Cdc42 signaling pathways effectively.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.5K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.8K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
14.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.8K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.0K